UnknownPhase 2NCT06031480
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Studying Combined hepatocellular carcinoma and cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Zhongshan Hospital
- Principal Investigator
- Jia FanShanghai Zhongshan Hospital
- Intervention
- Anlotinib and TQB2450(drug)
- Enrollment
- 55 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Zhongshan hospital, Shanghai, Shanghai Municipality, China
Collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06031480 on ClinicalTrials.govOther trials for Combined hepatocellular carcinoma and cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06902246Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular CarcinomaUniversity of Miami
- RECRUITINGPHASE1NCT07419841A Phase 1 Study of the Safety and Tolerability of CTX-10726Compass Therapeutics
- RECRUITINGPHASE1NCT07493044An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular CarcinomaGuangzhou FineImmune Biotechnology Co., LTD.
- RECRUITINGPHASE2NCT07122089Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisCenter Eugene Marquis
- RECRUITINGPHASE1, PHASE2NCT07482059A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaWest China Hospital
- RECRUITINGPHASE2NCT06254248Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07469319Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral CirrhosisUniversity of Aarhus
- RECRUITINGEARLY PHASE1NCT07242417TC-G203 for Patients With GPC3-Positive Advanced Solid TumorsBeijing GoBroad Hospital
See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →